Drug Discovery And Development
Cancer Research UK and the Institute of Cancer Research, London, join forces with Merck in new drug discovery alliance
Cancer Research UK and The Institute of Cancer Research, London announce a multi-project collaboration and licensing deal with Merck.
Cancer Research UK announces the signing of a five-year drug-discovery collaboration between its subsidiary, Cancer Research Technology, and Celgene Corporation
A trial to test an experimental drug in patients with head and neck cancer launches in the UK through the Combinations Alliance.
An ovarian cancer drug can leak through the blood brain barrier to reach brain tumours and could be an effective treatment for glioblastoma.
A clinical trial to test a new cancer drug in patients with advanced solid tumours, launches in four centres across the UK today.
An experimental treatment for bladder cancer will move into an early phase clinical trial under an agreement signed today.
Cancer Research UK, Cancer Research Technology and HitGen Ltd have entered into a licence agreement to develop a novel class of drugs in lung cancer.
Cancer Research Technology, UCL, and Tusk Therapeutics join forces to develop cancer immunotherapies
Cancer Research Technology, Tusk Therapeutics and UCL have signed an agreement to research, develop and commercialise an antibody-based therapeutic.
The Cancer Research Technology (CRT) Pioneer Fund announced an investment to develop a promising new class of drugs for blood cancer.
CRT and University of Manchester receive success payment from GlaxoSmithKline for cancer epigenetics research collaboration
Cancer Research Technology (CRT) has today received a success payment from GlaxoSmithKline resulting from its research collaboration.